A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
暂无分享,去创建一个
Susan O'Brien | Dan Jones | Rajyalakshmi Luthra | Lynne V Abruzzo | H. Kantarjian | F. Ravandi | L. Medeiros | L. Abruzzo | S. O'brien | Hui Yao | R. Luthra | Farhad Ravandi | Hagop M Kantarjian | Z. Zuo | L Jeffrey Medeiros | L. Medeiros | Deborah A Thomas | Su S. Chen | Zhuang Zuo | Hui Yao | Su S Chen | Dan M. Jones | D. Thomas
[1] A. Cherry,et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. , 2005, Blood.
[2] T. Naoe,et al. Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy , 2008, Haematologica.
[3] B. Druker,et al. Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib , 2006, Molecular and Cellular Biology.
[4] M. Relling,et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. , 2005, Cancer cell.
[5] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[6] M. Tallman,et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. , 2009, Blood.
[7] H. Gschaidmeier,et al. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). , 2003, Blood.
[8] R. Foà,et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] H. Kantarjian,et al. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. , 2008, Blood.
[10] H. Kantarjian,et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. , 2007, Blood.
[11] S. Raimondi,et al. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. , 1999, Blood.
[12] Steven M Kornblau,et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. , 2004, Blood.
[13] H. Kantarjian,et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Cheng Cheng,et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. , 2004, The New England journal of medicine.
[15] Yusuke Nakamura,et al. Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. , 2007, International journal of oncology.
[16] T. Barrette,et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. , 2007, Neoplasia.
[17] M. Slovak,et al. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. , 2008, Blood.
[18] T. Lipp,et al. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. , 2004, Blood.
[19] R. Foà,et al. The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial. , 2006, Haematologica.
[20] T. Naoe,et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. Downing,et al. Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions , 2009, Leukemia.
[22] J. Cigudosa,et al. Genetic and Epigenetic Silencing of microRNA-203 Enhances ABL 1 and BCR-ABL 1 Oncogene Expression , 2008 .
[23] J. Downing,et al. Satelite Symposium V, Meet-the-Professor Sessions I and II, Main Sessions I-IX , 2004, Annals of Hematology.
[24] Kevin R Coombes,et al. Validation of oligonucleotide microarray data using microfluidic low-density arrays: a new statistical method to normalize real-time RT-PCR data. , 2005, BioTechniques.
[25] Jill P. Mesirov,et al. Comparative gene marker selection suite , 2006, Bioinform..
[26] J. Hay,et al. A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia , 2007, Expert opinion on pharmacotherapy.
[27] J. Oldenburg,et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). , 2007, Blood.
[28] J. Melo,et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib , 2006, Leukemia.
[29] H. Kantarjian,et al. Kinase domain point mutations in Philadelphia chromosome‐positive acute lymphoblastic leukemia emerge after therapy with BCR‐ABL kinase inhibitors , 2008, Cancer.
[30] Cheng Cheng,et al. In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile , 2008, PLoS medicine.
[31] J. Downing,et al. A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. , 2007, Blood.
[32] J. Downing,et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.
[33] R. Arceci. Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia , 2010 .
[34] L. Medeiros,et al. TaqMan reverse transcriptase-polymerase chain reaction coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. , 2006, Methods in molecular biology.
[35] L. Tanoue. Cancer Statistics, 2009 , 2010 .
[36] J. Esteve,et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial , 2010, Haematologica.
[37] Christopher B. Miller,et al. BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros , 2008, Nature.
[38] Ching-Hon Pui,et al. Acute lymphoblastic leukemia. , 2004, The New England journal of medicine.
[39] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[40] M. Tallman,et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin , 2006, Blood.